Titagarh Rail Systems (NSE: TITAGARH) Q4 FY26 results: Why the order book looks strong but the FY27 execution test now matters more
Read More Pharma Industry News Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as… byPallavi MadhirajuNovember 14, 2024